NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

accusing GSK of hiding an internal report which suggested that Zantac might contain a cancer-causing compound. The lawsuit claims that GSK scientist Richard Tanner discovered in 1982 that when ...

All the companies have insisted they will defend themselves vigorously in the lawsuits ... or reliable evidence that ranitidine increases the risk of any cancer.” “Yesterday’s ruling ...

The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

the FDA requested that manufacturers cease selling Zantac and any generic alternatives. Tens of thousands of cancer-stricken patients filed personal injury and product liability lawsuits against ...

Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise ...

The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") . IF ...

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.

who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...